Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 2075

1.

Connectome sorting by consensus clustering increases separability in group neuroimaging studies.

Rasero J, Diez I, Cortes JM, Marinazzo D, Stramaglia S.

Netw Neurosci. 2019 Feb 1;3(2):325-343. doi: 10.1162/netn_a_00074. eCollection 2019.

PMID:
30793085
2.

Tyrosine Kinase Inhibitor Associated Fibrothorax.

Adrianza AM, Jimenez CA, Aldana GL, Pozo L, Cortes JE, Sagar AES.

Am J Respir Crit Care Med. 2019 Feb 20. doi: 10.1164/rccm.201806-1155IM. [Epub ahead of print] No abstract available.

PMID:
30785770
3.

Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators.

Forns J, Pottegård A, Reinders T, Poblador-Plou B, Morros R, Brandt L, Cainzos-Achirica M, Hellfritzsch M, Schink T, Prados-Torres A, Giner-Soriano M, Hägg D, Hallas J, Cortés J, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M, Reutfors J.

J Affect Disord. 2019 Feb 6;249:242-252. doi: 10.1016/j.jad.2019.02.010. [Epub ahead of print]

PMID:
30780117
4.

[Physical fitness of school age children post-implementation of an educational intervention to prevent childhood obesity in Morelos, Mexico.]

Gatica-Domínguez G, Moreno-Saracho JE, Cortés JD, Henao-Moran SA, Rivera JA.

Salud Publica Mex. 2019 Ene-Feb;61(1):78-85. doi: 10.21149/9389. Spanish.

PMID:
30753776
5.

[New cephalosporins].

Olarte-Luis T, Cáceres-Galíndez D, Cortés JA.

Rev Chilena Infectol. 2018;35(5):465-475. doi: 10.4067/s0716-10182018000500465. Spanish.

6.

Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC.

Ann Oncol. 2019 Jan 31. doi: 10.1093/annonc/mdz036. [Epub ahead of print]

PMID:
30715161
7.

NK-lysin from skin-secreted mucus of Atlantic salmon and its potential role in bacteriostatic activity.

Valero Y, Cortés J, Mercado L.

Fish Shellfish Immunol. 2019 Jan 29;87:410-413. doi: 10.1016/j.fsi.2019.01.034. [Epub ahead of print]

PMID:
30703553
8.

Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

Ortega V, Antón A, Garau I, Afonso N, Calvo L, Fernández Y, Martínez-García M, Blanco E, Zamora P, García M, Illarramendi JJ, Rodríguez Sánchez CA, Sampayo M, Aguirre E, Pérez-García JM, Cortés J, Llombart-Cussac A.

Clin Breast Cancer. 2018 Dec 20. pii: S1526-8209(17)30144-1. doi: 10.1016/j.clbc.2018.12.012. [Epub ahead of print]

PMID:
30679100
9.

Approaches to the mechanism of antifungal activity of Zuccagnia punctata-Larrea nitida bi-herbal combination.

Butassi E, Svetaz LA, Sortino MA, Quiroga AD, Carvalho VSD, Cortés JCG, Ribas JC, Zacchino SA.

Phytomedicine. 2018 Jul 6;54:291-301. doi: 10.1016/j.phymed.2018.06.045. [Epub ahead of print]

PMID:
30668380
10.

Actividad in vitro del tedizolid y de antibióticos de comparación en aislamientos de Staphylococcus aureus resistentes a meticilina en infecciones de piel y tejidos blandos en siete hospitales de Colombia.

Leal AL, Ovalle MV, Cortés JA, Montañes AM, De la Rosa ZR, Rodríguez JY, Gualtero S, Ariza B, Sussman O, Torres MDP.

Biomedica. 2018 Dec 1;38(4):507-513. doi: 10.7705/biomedica.v38i4.4022.

11.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.

Nat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.

12.

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.

Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F.

Clin Lymphoma Myeloma Leuk. 2018 Dec 20. pii: S2152-2650(18)30679-7. doi: 10.1016/j.clml.2018.12.009. [Epub ahead of print]

PMID:
30635233
13.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy535. [Epub ahead of print] No abstract available.

PMID:
30624662
14.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy529. [Epub ahead of print] No abstract available.

PMID:
30624616
15.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Cortes J, Massard C, Armand JP, Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy532. [Epub ahead of print] No abstract available.

PMID:
30624604
16.

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy534. [Epub ahead of print] No abstract available.

PMID:
30624599
17.

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy538. [Epub ahead of print] No abstract available.

PMID:
30624595
18.

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA.

Gao M, Callari M, Beddowes E, Sammut SJ, Grzelak M, Biggs H, Jones L, Boumertit A, Linn SC, Cortes J, Oliveira M, Baird R, Chin SF, Caldas C.

Genome Med. 2019 Jan 4;11(1):1. doi: 10.1186/s13073-018-0611-9.

19.

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.

Chamoun K, Kantarjian H, Atallah R, Gonzalez GN, Issa GC, Rios MB, Garcia-Manero G, Borthakur G, Ravandi F, Jain N, Daver N, Konopleva M, DiNardo CD, Kadia T, Pemmaraju N, Jabbour E, Cortes J.

J Hematol Oncol. 2019 Jan 3;12(1):1. doi: 10.1186/s13045-018-0686-1.

20.

Reply: Further evidence for a non-cortical origin of mirror movements after stroke.

Ejaz N, Xu J, Branscheidt M, Hertler B, Schambra H, Widmer M, Faria AV, Harran M, Cortes JC, Kim N, Celnik PA, Kitago T, Luft A, Krakauer JW, Diedrichsen J.

Brain. 2019 Jan 1;142(1):e2. doi: 10.1093/brain/awy309. No abstract available.

PMID:
30596904
21.

A second-generation TKI should always be used as initial therapy for CML.

Cortes JE.

Blood Adv. 2018 Dec 26;2(24):3653-3655. doi: 10.1182/bloodadvances.2018018655. No abstract available.

22.

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.

Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK, Rousselot P, Gambacorti-Passerini C.

J Hematol Oncol. 2018 Dec 27;11(1):143. doi: 10.1186/s13045-018-0685-2. Review.

23.

Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.

Pérez-Garcia J, Cortés J, Metzger Filho O.

Oncologist. 2018 Dec 21. pii: theoncologist.2018-0182. doi: 10.1634/theoncologist.2018-0182. [Epub ahead of print]

PMID:
30578311
24.

Hundreds of genetic barcodes of the species-rich hydroid superfamily Plumularioidea (Cnidaria, Medusozoa) provide a guide toward more reliable taxonomy.

Moura CJ, Lessios H, Cortés J, Nizinski MS, Reed J, Santos RS, Collins AG.

Sci Rep. 2018 Dec 20;8(1):17986. doi: 10.1038/s41598-018-35528-8.

25.

Ambulatory assessment of phonotraumatic vocal hyperfunction using glottal airflow measures estimated from neck-surface acceleration.

Cortés JP, Espinoza VM, Ghassemi M, Mehta DD, Van Stan JH, Hillman RE, Guttag JV, Zañartu M.

PLoS One. 2018 Dec 20;13(12):e0209017. doi: 10.1371/journal.pone.0209017. eCollection 2018.

26.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.

Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M.

Leukemia. 2019 Feb;33(2):379-389. doi: 10.1038/s41375-018-0312-9. Epub 2018 Dec 16.

27.

Realistic Ensemble Models of Intrinsically Disordered Proteins Using a Structure-Encoding Coil Database.

Estaña A, Sibille N, Delaforge E, Vaisset M, Cortés J, Bernadó P.

Structure. 2019 Feb 5;27(2):381-391.e2. doi: 10.1016/j.str.2018.10.016. Epub 2018 Dec 13.

PMID:
30554840
28.

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.

Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F.

Lancet Haematol. 2019 Jan;6(1):e29-e37. doi: 10.1016/S2352-3026(18)30182-0. Epub 2018 Dec 10.

PMID:
30545576
29.

[Cryptococcosis in Hospital Carlos Van Buren, Valparaiso: a clinical serie].

Cortés J, Kral A, Wilson G.

Rev Chilena Infectol. 2018 Aug;35(4):420-423. doi: 10.4067/s0716-10182018000400420. Spanish.

30.
31.

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.

Boddu PC, Kadia TM, Garcia-Manero G, Cortes J, Alfayez M, Borthakur G, Konopleva M, Jabbour EJ, Daver NG, DiNardo CD, Naqvi K, Yilmaz M, Short NJ, Pierce S, Kantarjian H, Ravandi F.

Cancer. 2018 Dec 6. doi: 10.1002/cncr.31885. [Epub ahead of print]

PMID:
30521114
32.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H.

Lancet Haematol. 2018 Dec;5(12):e618-e627. doi: 10.1016/S2352-3026(18)30176-5.

PMID:
30501869
33.

The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.

Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG.

Cancer. 2018 Nov 30. doi: 10.1002/cncr.31896. [Epub ahead of print]

PMID:
30500073
34.

Genetic Variation in Coat Colour Genes MC1R and ASIP Provides Insights Into Domestication and Management of South American Camelids.

Marín JC, Rivera R, Varas V, Cortés J, Agapito A, Chero A, Chávez A, Johnson WE, Orozco-terWengel P.

Front Genet. 2018 Nov 13;9:487. doi: 10.3389/fgene.2018.00487. eCollection 2018.

35.

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.

Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Stradella A, Morilla I, Viñas G, Cortés J, Cuyàs E, Verdura S, Fernández-Ochoa Á, Fernández-Arroyo S, Segura-Carretero A, Joven J, Pérez E, Bosch N, Garcia M, López-Bonet E, Saidani S, Buxó M, Menendez JA.

Oncotarget. 2018 Nov 2;9(86):35687-35704. doi: 10.18632/oncotarget.26286. eCollection 2018 Nov 2.

36.

Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study.

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J.

Ann Oncol. 2018 Nov 26. doi: 10.1093/annonc/mdy517. [Epub ahead of print]

PMID:
30475950
37.

Predicting functional networks from region connectivity profiles in task-based versus resting-state fMRI data.

Rasero J, Aerts H, Ontivero Ortega M, Cortes JM, Stramaglia S, Marinazzo D.

PLoS One. 2018 Nov 12;13(11):e0207385. doi: 10.1371/journal.pone.0207385. eCollection 2018.

38.

Modeling motor learning using heteroskedastic functional principal components analysis.

Backenroth D, Goldsmith J, Harran MD, Cortes JC, Krakauer JW, Kitago T.

J Am Stat Assoc. 2018;113(523):1003-1015. doi: 10.1080/01621459.2017.1379403. Epub 2017 Sep 29.

39.

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H.

Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774. [Epub ahead of print]

PMID:
30409776
40.

Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.

Cortes J, Rea D, Lipton JH.

Am J Hematol. 2019 Mar;94(3):346-357. doi: 10.1002/ajh.25342. Epub 2018 Nov 25. Review.

PMID:
30394563
41.

Synaptotagmin-1 overexpression under inflammatory conditions affects secretion in salivary glands from Sjögren's syndrome patients.

Cortés J, Hidalgo J, Aguilera S, Castro I, Brito M, Urra H, Pérez P, Barrera MJ, Carvajal P, Urzúa U, González S, Molina C, Bahamondes V, Hermoso M, González MJ.

J Autoimmun. 2019 Feb;97:88-99. doi: 10.1016/j.jaut.2018.10.019. Epub 2018 Oct 31.

PMID:
30391023
42.

Variable Neighborhood Search with Cost Function Networks To Solve Large Computational Protein Design Problems.

Charpentier A, Mignon D, Barbe S, Cortes J, Schiex T, Simonson T, Allouche D.

J Chem Inf Model. 2019 Jan 28;59(1):127-136. doi: 10.1021/acs.jcim.8b00510. Epub 2018 Nov 14.

PMID:
30380857
43.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.

EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.

44.

Positive and negative religious coping as predictors of distress among minority older adults.

O'Brien B, Shrestha S, Stanley MA, Pargament KI, Cummings J, Kunik ME, Fletcher TL, Cortes J, Ramsey D, Amspoker AB.

Int J Geriatr Psychiatry. 2019 Jan;34(1):54-59. doi: 10.1002/gps.4983. Epub 2018 Oct 30.

PMID:
30375027
45.

Nanocardboard as a nanoscale analog of hollow sandwich plates.

Lin C, Nicaise SM, Lilley DE, Cortes J, Jiao P, Singh J, Azadi M, Lopez GG, Metzler M, Purohit PK, Bargatin I.

Nat Commun. 2018 Oct 25;9(1):4442. doi: 10.1038/s41467-018-06818-6.

46.

Myocardial MIBG scintigraphy in genetic Parkinson's disease as a model for Lewy body disorders.

Gabilondo I, Llorens V, Rodriguez T, Fernández M, Concha TP, Acera M, Tijero B, Murueta-Goyena A, Del Pino R, Cortés J, Gómez-Esteban JC.

Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):376-384. doi: 10.1007/s00259-018-4183-0. Epub 2018 Oct 15.

PMID:
30324423
47.

CXCR4 antagonists for treatment of breast cancer.

Cortés J, Holgado E, Perez-Garcia J.

Oncotarget. 2018 Sep 11;9(71):33442-33443. doi: 10.18632/oncotarget.26090. eCollection 2018 Sep 11. No abstract available.

48.

Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value.

Hidalgo-Lόpez JE, Kanagal-Shamanna R, Quesada AE, Gong Z, Wang W, Hu S, Medeiros LJ, Bassett RL Jr, d'Orcy E, Yin CC, Cortes J, Jabbour EJ, Kantarjian HM, Bueso-Ramos CE.

Cancer. 2018 Oct 1;124(19):3849-3855. doi: 10.1002/cncr.31663. Epub 2018 Oct 15.

PMID:
30321462
49.

Mental Health Differences Between Older and Younger Lesbian, Gay, Bisexual, and Transgender Veterans: Evidence of Resilience.

Cortes J BA, Fletcher TL PhD, Latini DM PhD, MSW, Kauth MR PhD.

Clin Gerontol. 2019 Mar-Apr;42(2):162-171. doi: 10.1080/07317115.2018.1523264. Epub 2018 Oct 15.

PMID:
30321114
50.

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M.

Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018.

Supplemental Content

Loading ...
Support Center